AU6258999A - Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria - Google Patents

Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria

Info

Publication number
AU6258999A
AU6258999A AU62589/99A AU6258999A AU6258999A AU 6258999 A AU6258999 A AU 6258999A AU 62589/99 A AU62589/99 A AU 62589/99A AU 6258999 A AU6258999 A AU 6258999A AU 6258999 A AU6258999 A AU 6258999A
Authority
AU
Australia
Prior art keywords
diagnostic
compositions
methods
therapeutic applications
oligonucleotides targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62589/99A
Inventor
Wilfried Seifert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitagenix Inc
Original Assignee
Vitagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitagenix Inc filed Critical Vitagenix Inc
Publication of AU6258999A publication Critical patent/AU6258999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62589/99A 1998-09-16 1999-09-15 Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria Abandoned AU6258999A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10062598P 1998-09-16 1998-09-16
US10059898P 1998-09-16 1998-09-16
US10059198P 1998-09-16 1998-09-16
US10059998P 1998-09-16 1998-09-16
US60100599 1998-09-16
US60100598 1998-09-16
US60100625 1998-09-16
US60100591 1998-09-16
PCT/US1999/021950 WO2000015265A1 (en) 1998-09-16 1999-09-15 Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria

Publications (1)

Publication Number Publication Date
AU6258999A true AU6258999A (en) 2000-04-03

Family

ID=27493144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62589/99A Abandoned AU6258999A (en) 1998-09-16 1999-09-15 Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria

Country Status (2)

Country Link
AU (1) AU6258999A (en)
WO (1) WO2000015265A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL247600B (en) 2014-03-19 2022-06-01 Ionis Pharmaceuticals Inc Compositions for modulating ataxin 2 expression
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
AU2015372560B2 (en) * 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2019310097A1 (en) 2018-07-25 2021-02-04 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ATXN2 expression
WO2023213943A1 (en) 2022-05-06 2023-11-09 The University Of Bristol Diagnostic method and kit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294533A (en) * 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
EP0973886B1 (en) * 1997-01-24 2005-03-23 AVI BioPharm, Inc. Method and conjugate for treating helicobacter pylori infections

Also Published As

Publication number Publication date
WO2000015265A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
AU2790199A (en) Biochemical compositions used in human treatment
AU1328502A (en) Novel targeted compositions for diagnostic and therapeutic use
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001255524A1 (en) Compositions and methods for the therapy and diagnosis of acne vulgaris
AU2002240312A1 (en) Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
EP0841936A4 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001289308A1 (en) Targeted agents useful for diagnostic and therapeutic applications
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3816697A (en) Conservin compositions and therapeutic and diagnostic uses therefor
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
IL159119A0 (en) Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU1462801A (en) Tissue specific genes of diagnostic import
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU3896900A (en) Treatment of pain
AU2530199A (en) Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU6258999A (en) Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase